DREADD
Designer receptors exclusively activated by designer drugs (DREADDs) are genetically engineered GPCRs that are activated by physiologically inert synthetic small molecules (designer drugs) but not their endogenous ligand. Read our DREADDs mini-review or for practical advice on using these ligands in the lab see Stability of Water-Soluble DREADD Ligands in Solution: A Technical Review and Clozapine N-Oxide (freebase) - a technical review on stability, solubility and use in the lab).
Clozapine N-oxide (CNO) (freebase) (HB1807)
Description:Prototypical DREADD activator. Clozapine metabolite.
Purity:>98%
- Description:
Dihydrochloride salt of CNO - the prototypical DREADD activator
Purity:>98%
±-Octopamine hydrochloride (HB2791)
Description:Invertebrate neurotransmitter. Chemogenetic DmOctβ1 receptor activator.
Purity:>99%
Perlapine (HB4889)
Description:Effective agonist for muscarinic-based DREADDs in vitro and in vivo. Non-CNO chemogenetic actuator
Purity:>98%
- Description:
Effective agonist for muscarinic-based DREADDs in vitro and in vivo. Non-CNO chemogenetic actuator. Water soluble.
Purity:>98%
Diphenhydramine hydrochloride (DPH) (HB2617)
Description:Histamine H1 antagonist. Potent actuator of a modified hM4Di "GRANPA" DREADD receptor.
Purity:>99%